GSK, the top 10 pharmaceutical companies with global market value in 2017, slipped out of the list

[market analysis of chinapharma.com] on November 27, the website of the world famous biotechnology media Gen (genetic engineering and biotechnology news magazine) released the top 10 pharmaceutical companies in 2017 ranked by market value On the whole, most pharmaceutical companies seem to be doing well this year The following is the list of top 10 pharmaceutical companies this year According to the market value as of November 9, 2017, the data comes from the company's website, stock trading website and other public channels The data of non-U.S companies are converted into US dollars according to the exchange rate of that day Top 10 pharmaceutical companies with high global market value (unit: US $100 million) pharmaceutical companies are relatively smooth Generally speaking, most of the traditional pharmaceutical companies are more smooth than biotechnology companies this year When biotechnology companies fall into the disappointing results of clinical trials or the unfavorable factors of failure in Q3, most of the pharmaceutical companies look smooth this year As of November 9, 2017, the Arca Pharmaceutical Stock Index of the New York Stock Exchange increased by 7.8% to $536.86 compared with the same period last year, while the market value of top 10 pharmaceutical companies in Gen's list reached $1.722 trillion this year, an increase of 9.8% over $1.568 trillion of the top 10 companies last year, and an increase of 5.9% over $1.626 trillion of the top 10 companies in 2015 Gen explained this reason with five factors: • the sales of heavy bomb drugs with an annual sales volume of more than US $1 billion continued to grow; • under the leadership of Scott Gottlieb, the new director of FDA, simplified the new drug listing procedures, and more new drugs were approved; • the corporate tax reduction policies launched by the government; • the policies aimed at reducing drug prices were not implemented as scheduled • pharmaceutical companies shift from large-scale M & A to small-scale reinforcement acquisition GSK slipped out of the list Compared with last year, only one company, GlaxoSmithKline (No 6 in 2016), slipped out of the list this year, with a market value of 66.38 billion pounds (about 87.29 billion US dollars), 16% lower than last year's 103.82 billion US dollars Lilly, which replaced GSK in the top 10, ranked No 11 last year with a market value of 86.63 billion US dollars What's more encouraging is that in addition to MSD, the market value of each of the top 10 pharmaceutical companies has increased this year compared with last year, and the ranking of Alberto and Bayer has been improved However, MSD dropped 1 to 6 from 2016, and was surpassed by the 7th Alberto in last year
On October 27, 2017, MSD announced that Q3 revenue decreased by 2% year-on-year, from $10.536 billion in Q3 in 2016 to $10.325 billion MSD provided several reasons for the decline in revenue For example, this year, MSD suffered a cyber attack that resulted in the shutdown of 9-price jiadasheo, resulting in a loss of sales revenue of $135 million, which was actually a $240 million 9-price jiadasheo order reserved for the US CDC Single
Other reasons include a 3% drop in drug sales to US $9.2 billion, mainly due to the cliff faced by the downshifted sterol drugs zetia and Vytorin, which lost market monopoly in the United States at the end of last year and early April of this year In addition, cupicin, the antibiotic of cubist, which was purchased at the end of 2014, was used for injection In Europe, REMICADE (infliximab) also faces the competition of bio generic drugs Original title: GSK, the top 10 pharmaceutical company with global market value, slipped out of the list in 2017, and MSD suffered a bad year